Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alok Shetty
Observed names:
Dr Alok Shetty,
Shetty, Alok
Institutions:
Homi Bhabha National Institute,
Tata Memorial Hospital
Observed institutions:
Homi Bhabha National Institute,
Chinese Academy of Medical Sciences & Peking Union Medical College,
Tata Memorial Hospital,
Dana-Farber Cancer Institute,
Institute of Hematology & Blood Diseases Hospital
ORCID:
0000-0001-5423-9832
Observed ORCID:
0000-0001-5423-9832
OpenAlex ID:
A5045847311
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation
2023
·
Vijay Maruti Patil
, Vanita Noronha
, et al.
·
Journal of Clinical Oncology
·
105
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
2024
·
Jessy Xinyi Han
, Min Jung Koh
, et al.
·
Blood Advances
·
17
PDF
High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial
2023
·
Hasmukh Jain
, Atharva Karulkar
, et al.
·
Blood
·
15
Implementation of a CAR-T cell therapy program in India
2025
·
Hema Hotchandani
, Manju Sengar
, et al.
·
Expert Review of Anticancer Therapy
·
7
Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile
2024
·
Hasmukh Jain
, Atharva Karulkar
, et al.
·
Blood
·
7
Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
2024
·
Gojiri Mawalankar
, Aarti Ramesh Achrekar
, et al.
·
Blood
·
6
Clinical Utility of Stepwise Bronchoalveolar Lavage Fluid Analysis in Diagnosing and Managing Lung Infiltrates in Leukemia/Lymphoma Patients With Febrile Neutropenia
2024
·
Jayashree Thorat
, Surabhi Bhat
, et al.
·
JCO Global Oncology
·
6
PDF
A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy
2023
·
Mounika Boppana
, Manju Sengar
, et al.
·
Indian Journal of Hematology and Blood Transfusion
·
6
PDF
Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center
2022
·
Rup J. Sarma
, Vijay M. Patil
, et al.
·
Cancer Research Statistics and Treatment
·
6
Forecasting optimal treatments in relapsed/refractory mature T‐ and NK ‐cell lymphomas: A global PETAL Consortium study
2025
·
Mark N. Sorial
, Jessy Xinyi Han
, et al.
·
British Journal of Haematology
·
5
PDF
Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population
2025
·
Hasmukh Jain
, Thomas Eipe
, et al.
·
JCO Global Oncology
·
5
Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML
2026
·
Gojiri Mawalankar
, Aarti Achrekar
, et al.
·
JCO Global Oncology
·
3
Attrition Rates in Multiple Myeloma - A Report from indian Patients at A Tertiary Cancer Center
2025
·
Dhyey Mishra
, Aditya Nair
, et al.
·
Indian Journal of Hematology and Blood Transfusion
·
3
PDF
Palliative Care Needs in Adult Patients with Acute Leukemia: A Prospective Observational Study
2025
·
Jyothsna Kuriakose
, Jayita K. Deodhar
, et al.
·
Journal of Palliative Medicine
·
3
Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia
2024
·
Nikhil Patkar
, Aarti Ramesh Achrekar
, et al.
·
Blood
·
3
Prognostic Significance of Wilms' Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2024
·
Priyanka Rajesh Ugale
, Aarti Ramesh Achrekar
, et al.
·
Blood
·
3
PDF
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
2023
·
Atharva Karulkar
, Ankesh Kumar Jaiswal
, et al.
·
Blood
·
3
PDF
A prospective observational study to compare the efficacy, time toxicity, and cost of conventional 3+7 regimen versus azacitidine + venetoclax (AZA + VEN) as induction therapy in patients with acute myeloid leukemia (AML).
2026
·
Manju Sengar
, Arvind Vaidyanathan
, et al.
·
Journal of Clinical Oncology
·
2
Acute myeloid leukaemia (AML) harbouring KMT2A -PTD: should it be considered as a myelodysplasia-related abnormality?
2026
·
Narasimhapriyan Kannan
, Aarti Achrekar
, et al.
·
Journal of Clinical Pathology
·
2
Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment
2024
·
Chandran K Nair
, Lingaraj Nayak
, et al.
·
Blood
·
2
PDF
Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial
2024
·
Hasmukh Jain
, Atharva Karulkar
, et al.
·
Blood
·
2
PDF
To Study Outcomes in Young CML Treated with TKI. a Registry Data from Hematological Cancer Consortium (HCC) of India
2023
·
Rajan Kapoor
, Laboni Sarkar
, et al.
·
Blood
·
2
PDF
Safety and feasibility of outpatient induction with intensive monitoring in AML: pilot study and extension cohort
2026
·
Hasmukh Jain
, Alok Shetty
, et al.
·
Blood Global Hematology
·
1
PDF
Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium
2025
·
Mark Sorial
, Kenechukwu Aniagboso
, et al.
·
Blood
·
1
Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.
2025
·
Hasmukh Jain
, Atharva Karulkar
, et al.
·
Blood
·
1
PDF
Show more works
View as search
Works count:
99
Citation count:
223
H-index:
6
I10-index:
3
Year
Topic
Type